Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022. In the quarter to June 2026, revenue fell 57.1%, EPS grew 99.5% and free cash flow grew 167.7%, each against the same quarter a year earlier.
Follow IBO
Impact Biomedical Inc. (IBO) P/E ratio
As of 16 October 2026, Impact Biomedical Inc. (IBO) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (June 2026) to 19.9× (November 2024); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.5× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVM Cel-Sci Corporation compare | n/m |
| ATOS Atossa Therapeutics, Inc. compare | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| IGC IGC Pharma, Inc. compare | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| ABVC ABVC BioPharma, Inc. compare | n/m |
| BYSI BeyondSpring Inc. compare | n/m |
| CYAD Celyad SA compare | n/m |
| IBO Impact Biomedical Inc. | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)